Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
Titel:
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
Auteur:
de Bono, J.S. Molife, L.R. Sonpavde, G. Maroto, J.P. Calvo, E. Cartwright, T.H. Loesch, D.M. Feit, K. Das, A. Zang, E.A. Wanders, J. Agoulnik, S. Petrylak, D.P.